Bunion-Like Toes and Tumor Like Swellings – Recognize FOP and Improve Patient Outcomes in the Era of Disease Specific Therapy
Released On
September 13, 2024
Expires On
September 10, 2025
Media Type
Internet
Completion Time
60 minutes
Specialty
Acute Care, Emergency Medicine, Genetics, Hematology-Oncology, Hospitalist, Infectious Disease, Neonatology, Pathology, Pediatrics, Pharmacy, Primary Care, Radiology, Rheumatology, Surgery
Topic(s)
Oncology, Pediatrics, Radiology
This activity is jointly provided by P2P Syncro, International Fibrodysplasia Ossificans Progressiva Association (IFOPA), and Partners for Advancing Clinical Education.
This activity is supported by an independent grant from Ipsen Pharmaceuticals.
Credit Available
- Physicians — maximum of 1 AMA PRA Category 1 Credits™
- Nurses — 1 Nursing Contact Hour
- Physician Assistants — 1 CE Credit
- Pharmacists — 1 Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity is designed to meet the educational needs of healthcare providers in pediatrics, primary care, oncology, surgery, radiology, acute care, emergency medicine, rheumatology, and infectious disease.
Program Overview
Bunion-like toes present at birth and tumor-like swellings in a young child are diagnostic signs of fibrodysplasia ossificans progressive (FOP), a disease with recent advances made in therapy. Upon completion of the course, learners should be able to associate great toe deformities with FOP and avoid misdiagnosing FOP as soft tissue sarcoma. Biopsy for “tumor” should be avoided in FOP.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Recognize that great toe deformities and soft tissue swellings are diagnostic signs for FOP.
- Add FOP to the differential diagnosis for tumors and avoid biopsy in suspected cases.
- Manage and treat FOP in the era of disease specific therapies.
Faculty
Christiaan Scott, MBChB
Dr. Christiaan Scott is a pediatric rheumatologist and Professor in the Department of Pediatrics at the University of Ottawa, Canada. He is also an Honorary Professor of Pediatrics at the University of Cape Town, South Africa. Dr. Scott is an internationally recognized expert in the field of fibrodysplasia ossificans progressive (FOP).
Michelle Davis
Michell Davis is the Executive Director of the International Fibrodysplasia Ossificans Progressiva Association (IFOPA). IFOPA is the leading FOP patient advocacy organization dedicated to raise awareness and fund research for finding a cure of FOP. It supports, connects, and advocates for FOP patients and their families worldwide.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and P2P Syncro. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Education
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.
Pharmacy Continuing Education
PACE designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008073-9999-24-215-H01-P)
Type of Activity: Knowledge
For Pharmacists: Upon successfully completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
PA Continuing Medical Education
PACE has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 9/12/2025. PAs should only claim credit commensurate with the extent of their participation.
Disclosures of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
- Dr. Christiaan Scott, faculty for this educational activity, has the following relevant financial relationships:
- Consultant, Advisor, or Speaker : Ipsen
- Michelle Davis faculty for this educational activity, has no relevant financial relationships.
Instructions for Participation and Credit
Participation in this self-study activity should be completed in approximately 1.0 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from September 13, 2024 through September 10, 2025
- Review the objectives and disclosures
- Study the educational content
- Visit https://partnersed.com
- Complete activity post-test(s)
- Complete the activity evaluation
You must respond to all evaluation questions to receive a certificate.
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better (if applicable) and the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has been posted.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For additional information about the accreditation of this activity, please visit https://partnersed.com.